TriangleNCT03846427 · OUTCOME
Maximum Observed Concentration (Cmax)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- nanograms/milliliter
- Interval / dispersion
- Standard Deviation
- Time frame
- Predose (within 30 min prior to dose) and 0.5, 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (28 days per cycle)
Analysis population: Pharmacokinetic analysis set included all participants who had at least 1 postdose zanubrutinib plasma concentration
Groups in this outcome
Zanubrutinib
Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent
| Group | Source count |
|---|---|
| Zanubrutinib | 11 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Zanubrutinib | 315.5 | 120.2 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 120.2
- value
- 315.5
- denoms
- counts
- group Id
- OG000
- value
- 11
- units
- Participants
- dispersion Type
- Standard Deviation
- groups
- description
- Zanubrutinib 160 mg (two 80-mg capsules) orally twice daily with or without food until progressive disease, intolerable toxicity, or withdrawal of consent
- id
- OG000
- title
- Zanubrutinib
- param Type
- MEAN
- population Description
- Pharmacokinetic analysis set included all participants who had at least 1 postdose zanubrutinib plasma concentration
- reporting Status
- POSTED
- time Frame
- Predose (within 30 min prior to dose) and 0.5, 1, 2, 3, 4, and 6 hours postdose on Cycle 1 Day 1 (28 days per cycle)
- title
- Maximum Observed Concentration (Cmax)
- type
- SECONDARY
- unit Of Measure
- nanograms/milliliter
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice